Peer-reviewed veterinary case report
Maximum safe oral cyclophosphamide dose for cats with tumors
By Chan, C M et al.·Published in Veterinary journal (London, England : 1997)·2020·The Pet Oncologist, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I dose escalating study of oral cyclophosphamide in tumour-bearing cats.
- Species:
- cat
Plain-English summary
A group of 46 cats with tumors were treated with oral cyclophosphamide, a medication used for cancer, to find the highest safe dose. The study determined that a dose of 460 mg/m was the maximum tolerated amount, given every two to three weeks, with careful monitoring of blood counts. While most cats tolerated the treatment well, some experienced a drop in white blood cells, known as neutropenia, which can increase infection risk. The cats were also treated with prednisolone and L-asparaginase, and the combination was deemed safe.
People also search for: cat cancer treatment · oral cyclophosphamide for cats · side effects of cyclophosphamide in cats
Abstract
Cyclophosphamide is an alkylating agent used to treat cats with lymphoma, carcinomas and sarcomas. However, no clear consensus exists regarding the maximum tolerated dose (MTD) of oral cyclophosphamide in cats. Toxicities are rarely reported at published oral dosages of cyclophosphamide (200-300 mg/m). The primary aim of this prospective study was to determine the MTD of oral cyclophosphamide in tumour-bearing cats via a modified phase I trial. A secondary aim was to define any toxicity. Forty-six client-owned tumour-bearing cats were enrolled. The cyclophosphamide dosage was escalated by approximately 10% (300, 330, 360, 400, 440, 460 and 480 mg/m) in cohorts of at least six cats. The MTD of oral cyclophosphamide in this study was 460 mg/mwith an inter-treatment interval of two to three weeks. Haematology is recommended 7 and 14 days after first cyclophosphamide treatment, and immediately before each subsequent dosage of cyclophosphamide or any potentially myelosuppressive chemotherapy agent. The dose-limiting toxicity was neutropenia with nadir at 7-21 days. This higher dosage was considered safe in combination with prednisolone and L-asparaginase. However, the higher dose of oral cyclophosphamide has not been evaluated in combination with other chemotherapy agents and thus should not be administered with these agents.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32564869/